Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Viking Therapeutics appointed Dorothy Gemmell to its Board of Directors, effective immediately, adding over 25 years of healthcare commercialization experience. Gemmell, a former executive at GoodRx and Capsule, brings expertise in scaling organizations and developing revenue models to the biotech's board.
Key figures
- Drug Name
- VK2735
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.